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Abstract
Background: Sphingosine-1 receptor 1 (S1P1) plays a major role in regulating lymphocyte egress from peripheral
lymph tissue. Lymphocyte trafficking is potentially a critical response to tumors and to tumor vaccines. Also, the
receptor has been shown to influence metastasis. However, there is little information on its expression in the aged
ovary or ovarian tumors. As a basis for further studies in the laying hen model of spontaneous ovarian cancer, the
objective of this study was to determine if S1P1 is expressed in hens, and if the morphological distribution of S1P1
is similar in hen and human ovary and ovarian tumors.
Methods: S1P1 mRNA was ascertained in hen tissue by RT-PCR using hen specific primers. S1P1 protein expression
and localization was evaluated in hen and human tissue with a human S1P1 antibody by Western blot and
immunohistochemistry.
Results: S1P1 mRNA was expressed in all hen tissues examined. Protein was detected in human and hen ovary
and ovarian tumors at 47, 72 and 108 kDa in Western blots. S1P1 was similarly expressed on endothelial cells,
lymphocytes and surface epithelial cells in normal ovaries and tumor-containing ovaries of the hen. In addition,
S1P1 distribution was heterogeneous in both hen and human ovarian tumors by immunohistochemistry.
Conclusion: The results show that S1P1 is expressed in the hen and human ovary as well as in ovarian tumors.
These findings support the use of the hen in further studies of the role of S1P1 in metastasis and immune cell
trafficking in ovarian tumor development.
Background
Sphingolipids acting through sphingosine-1-phosphate
receptors are involved in embryogenesis, angiogenesis,
vascular homeostasis and immune cell trafficking [1,2].
There are five isoforms of sphingosine receptors (S1P1 -
S1P5) [3]. Sphingosine receptors are members within a
larger family of G-Protein Coupled Receptors (GPCR)
that are expressed on leukocytes and on vascular
endothelial cells. The ligand, sphingosine-1 phosphate
(S1P), binds to several of the sphingosine 1-phosphate
receptors with higher affinity to the S1P1 and S1P3 iso-
forms [4]. The S1P1 regulates lymphocyte egress from
lymphoid organs [5,6] and is necessary for lymphocyte
recirculation from thymus and peripheral lymphoid
organs. In addition to a critical role in regulating
immune cell trafficking, activation of S1P1 can promote
or inhibit apoptosis of immune cells depending on the
balance of cytokines [7]. Knockout of S1P1 (LP(B1)/
EDG-1) in mice is embryologically lethal [8]. S1P1 also
has a role in inflammatory diseases such as graft versus
host disease and multiple sclerosis [9]. The drug
FTY720 binds to S1P1 as a high affinity agonist and
causes down-regulation and internalization of S1P1.
This drug has been used as a novel immunosuppressive
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from lymph to sites of inflammation and is of particular
interest in transplant and in treatment of autoimmune
diseases such as multiple sclerosis [9] and more recently,
cancer.
The endogenous ligand (S1P) was recently shown to
play an important role in ovarian cancer invasiveness
and ovarian tumor cell migration [10,11]. It also appears
to protect ovaries from the effects of chemotherapy [12]
and radiation [13] and, therefore, is potentially a thera-
peutic target to preserve fertility in patients undergoing
therapy for cancer. While there are several studies of
S1P involvement in ovarian cancer models and ovarian
tumor-derived cell lines there is no information on the
expression of its receptor, S1P1, in normal human
(aged) ovary or in naturally occurring ovarian tumors in
humans or animal models.
We [14-18] and others [19-21] reported that the laying
hen, which spontaneously develops ovarian tumors [22]
is useful for studies of ovarian cancer. The normal hen
ovary has been used extensively to understand ovarian
physiology [23,24] because it shares many features of
normal human ovary including similar cyclic hormone
regulation of follicle development and ovulation [25].
Like human ovaries, hen ovaries express receptors for
follicle stimulating hormone (FSH) and luteinizing hor-
mone (LH) and produce inhibins, estrogen, and proges-
terone in response to FSH and LH [24]. One difference
between human and hen ovarian function is the lack of
post-ovulatory development of a progesterone-secreting
corpus luteum and the events that lead to implantation
because eggs are laid externally.
Likewise, naturally occurring hen ovarian tumors are
similar to human tumors [17,22]. Commonly, hen ovar-
ian tumors exhibit epithelial cell histology including ser-
ous, endometrioid, clear cell and mucinous histology [17]
and less frequently tumors of germ cell origin [22] which
is typical of the histology seen in humans [26]. The inci-
dence of both hen and human ovarian tumors increases
with age [22,27]. In hens, which are pure bred (rather
than inbred), the incidence of ovarian tumors is also
strain and flock dependent [20] which suggests a genetic
component associated with ovarian cancer, as in humans
[28]. As well, many of the same proteins are expressed in
human and hen tumors such as CA125 [29], E-cadherin
[30], COX [19], p53 [28], SBP-1 [31], mesothelin [32] and
several others [21]. Interestingly, progesterone reduced
the incidence of ovarian carcinoma in hens which paral-
lels the reduced risk of ovarian cancer associated with
oral contraceptive use in women [33]. Recently, we devel-
oped the use of ultrasound to assess ovarian morphology
and tumor-associated angiogenesis [18] in order to facili-
tate the selection of hens for studies of ovarian cancer
and to be able to monitor hens longitudinally.
A further advantage of the hen as a model for studies
of immune mechanisms in ovarian cancer is the well
established knowledge of the hen immune system. In
fact, the two different types of immune cells (T and B
cells) were first described based on the differences in
lymphocytes in the thymus and bursa of Fabricius
[34,35]. Also, the first successful anti-tumor vaccine was
developed for chickens to prevent Marek’s disease, a
virally-induced lymphoid neoplasm [36]. Moreover,
humans [37,38] and hens [16] develop spontaneous
ovarian autoimmunity and circulating anti-ovarian anti-
bodies associated with prematurely reduced ovarian
function.
Our future objective is to examine the role of immu-
nity in ovarian tumor development and progression
through modification of lymphocyte trafficking.
Although the expression and role of S1P1 has been
demonstrated in humans, there is little information on
its expression in the human or hen ovary. Therefore,
the specific objective of this study was to determine if
S1P1, a major receptor that regulates lymphocyte traf-
ficking in humans, is expressed in hens, and if the mor-
phological distribution of S1P1 is similar in hen and
human ovary and ovarian tumors.
Methods
Animals
White leghorn hens (2-3 years old, strain W/96) were
housed at the University of Illinois at Urbana-Cham-
paign (UIUC) at the Poultry Research Farm affiliated
with the Department of Animal Science. Food and water
were given ad libitum and hens were maintained on a
17:7 hour light: dark schedule. Hens this age were used
in our study because the proportion of hens with ovar-
ian tumors is about 10-15%, based on our experience.
Animals were selected for study based on normal or
abnormal ovarian ultrasound as described previously
[15,17,18]. Hens were sacrificed at UIUC by cervical dis-
location and organs removed. Hen ovaries (n = 30) were
histologically staged and typed by a pathologist using
criteria similar to human tumor type and staging as
described previously [17]. All procedures were approved
by the University of Illinois Institutional Animal Care
and Use Committee (IACUC).
Human Ovarian Tissues
Normal ovaries and ovarian tumors were obtained from
the gynecologic oncology clinics at Rush University
Medical Center and John Stroger Hospital (Chicago, IL)
according to Institutional Review Board (IRB) approved
protocols. The criterion for inclusion in the study was
women ≥ 45 years old. The criteria for exclusion were a
previous history of any cancer and prior chemotherapy
or radiation treatment. Normal ovaries were obtained at
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tumors were obtained from patients with malignant
tumors (n = 5; mean age 64 ± 15 years). The tumor his-
tology and tumor grade were determined by a patholo-
gist using standard FIGO criteria [17]. Of the five
ovarian tumors shown in this report, three were serous
and two were endometrioid.
Tissue preparation
H e no v a r y( n=3 0 ) ,s p l e e n( n=5 ) ,a n dc a e c a lt o n s i l s
(peripheral lymphoid organ, n = 4) and brain (n = 2)
were cut into three equal portions. There were 11 nor-
mal ovaries and 19 ovarian tumors used for these
experiments. Tissues were prepared for histological and
biochemical analysis. All ovarian tissue was examined to
verify normal or tumor histology (n = 30). For immuno-
histochemical analysis, 23 tissues were used and for
Western blot and PCR, 20 and 30 tissues were used,
respectively. Human (normal ovary, n = 5) and ovarian
tumors (n = 5) were similarly prepared. One portion
was fixed in 10% PBS-buffered formalin and embedded
in paraffin for histology and immunohistochemistry
[17]. Sections of formalin-fixed, paraffin-embedded tis-
sue stained with Hematoxylin and Eosin (H/E) were
examined by a pathologist to determine the histological
type and stage. A second portion was frozen (-80°C) for
cryostat sections for immunohistochemistry. The final
portion was washed with cold 1.5 mM Tris HCl, homo-
genized (100 mg wet weight tissue/100mL of 40 mM
Tris HCl, 5 mM MgSO4 buffer), centrifuged (1,000 × g,
10 minutes, 4°C) and the supernatant stored at -80°C
for Western blot analysis [16,31]. In addition, to enrich
for S1P1 receptors, the supernatant was centrifuged
again (18,000 × g, 40 minutes, 4°C) and the pellet was
suspended in sample buffer (Bio-Rad Laboratories, Her-
cules, CA) for one-dimensional gel electrophoresis (1D-
PAGE). Rat brain was used for control and was a gift
from Dr. Amanda Mickiewicz (Rush University,
Chicago).
Reverse transcription-polymerase chain reaction (RT-PCR)
To assess S1P1 mRNA expression, RT-PCR was per-
formed as reported previously [38]. Briefly, total RNA
from 30 ovaries (11 normal and 19 tumor) and 14
organs was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA). The RNA content was measured at an
optical density (OD) of 260 nm and the purity evaluated
using an OD 260/280 nm absorbance ratio ≥ 1.7. RNA
was treated with DNASe (Invitrogen, Carlsbad, CA) to
remove trace amounts of genomic DNA before the first
strand synthesis. First strand synthesis was performed
using 500 ng of RNA according to the manufacturer’s
protocol (37°C, 1 hour; High Capacity cDNA RT Kit,
(Applied Biosystems, Carlsbad, CA). The PCR
amplifications were carried out in a 25 μl reaction
volume containing 25 ng of cDNA using Platinum Taq
DNA Polymerase (Invitrogen, Carlsbad, CA) according
to the manufacturer’s recommendation. The PCR cycle
consisted of a primary denaturation at 94°C (3 minutes)
followed by 35 cycles of denaturation at 94°C (30 sec-
onds) and 54°C (30 seconds) to anneal and 72°C (1 min-
ute) for extension followed by a final extension at 72°C
(10 minutes) in a programmable Peltier Thermo Cycler
(PTC-200, MJ Research Inc., Ramsey, MN). Hen-specific
S1P1 primers were designed using Oligoperfect Designer
software (Invitrogen, Carlsbad, CA) using the S1P1
sequence from the NCBI [GeneBank: XM_422305.2].
The forward primer was CCCCAGGAGCAT-
TAAAACTG and the reverse primer was CTGCTGAC-
CACCCTCACTG located between exons 1 and 2.
b-actin was used as the endogenous control with a for-
ward primer of TGCGTGACATCAAGGAGAAG and a
reverse primer of ATGCCAGGGTACATTGTGGT. The
expected base pair size for the S1P1 amplicon was 226
bp and for b-actin was 300 bp. PCR amplicons were
visualized in a 2% agarose gel (Pierce/Thermo Fisher,
Rockford, IL USA) in T.A.E. buffer (4.84g Tris Base,
1.14mL acetic acid, 2.0 mL 0.5M EDTA/L of buffer) and
stained with ethidium bromide. The image was captured
using a ChemiDoc XRS system (Bio-Rad, Hercules, CA).
Amplicon from a positive sample (endometrioid carci-
noma of the ovary) was used for sequence analysis after
purification using the Quia-Quick PCR Purification Sys-
tem (Qiagen, Valencia, CA USA) according to manufac-
turer’s instructions. The purified DNA was sequenced at
the DNA sequencing facility at the University of Illinois
at Chicago using an ABI 3100 Genetic analyzer (Applied
Biosystems, Foster City, CA).
One-dimensional (1D) Western Blot
Some ovarian tissue samples (n = 20; 9 normal, 11
tumor) were homogenized according to a previous pro-
tocol [39] and stored at -80°C. Proteins (10 μg/lane)
were separated by 1D gel electrophoresis using 10% gra-
dient Tris-HCl gels (Bio-Rad, Hercules, CA) using stan-
dard procedures [31]. MagicMark XP Western blot
standards (Invitrogen, Carlsbad, CA) were used to esti-
mate molecular weight. Rat brain (n = 3) was used as a
positive control (recommended by Cayman Chemical
website). Proteins were tran s f e r r e d( 1 8V o l t s ,3 0m i n -
utes) to a nitrocellulose membrane (0.45 μm; Bio-Rad,
Hercules, CA). Blots were blocked in 10 × Blocking Buf-
fer (diluted to 1×; Sigma St. Louis, MO) containing
0.05% Tween-20 (4°C; 16 hours; Sigma, St. Louis, MO),
rinsed in Wash buffer (0.15 M NaCl in 10 mM Tris
containing 0.05% Tween-20, pH7.5) and incubated in
rabbit anti-S1P1 polyclonal antibody (1:200; Cayman
Chemical, Anne Arbor MI) diluted in blocking buffer
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brane was washed three times in cold Wash buffer fol-
lowed by goat anti-rabbit immunoglobulin-HRP
(Horseradish - Peroxidase; Pierce/Thermo Fisher, Rock-
ford, IL). As a control for antibody specificity the anti-
S1P1 antibody was pre-absorbed with blocking peptide
( C a y m a n ,A n nA r b o r ,M I )( 1 : 1 ,v / v ;4 5m i n u t e s ,2 2 ° C ) .
The absorbed, control anti-S1P1 was diluted to the same
concentration as the untreated S1P1 antibody (1:200) in
blocking buffer (Sigma, St. Louis MO) supplemented
with 0.05% Tween-20 and used as primary antibody. The
reaction was developed in Super Signal West Dura sub-
strate (Pierce/Thermo Fisher, Rockford, IL) and digital
images acquired using a ChemiDoc XRS system (Bio-
Rad, Hercules, CA). Digital images were analyzed by
Quantity One software (Bio-Rad, Hercules, CA).
Because there are currently no commercially available
antibodies against avian S1P1, we used a commercially
available polyclonal antibody against human S1P1 for
Western blotting and immunohistochemical experi-
ments. There are two serine (S) to threonine (T) substi-
tutions in the chicken S1P1R, within amino acids 241-
253 of the epitope, and a high degree of homology (>
85% based on sequence comparisons) between the two
proteins.
Immunohistochemistry
For cryostat sections, tissue was washed in cold phos-
phate buffered saline (PBS, pH 7.0) and placed in 30%
sucrose overnight at 4°C. Tissues were washed once
more in PBS the following morning, embedded in OCT
Compound (Tissue Tek, Sakura, Japan) and flash frozen
in dry-ice cooled methanol and stored at -80°C until use.
Ovarian sections were incubated with rabbit anti-S1P1
(Cayman, Ann Arbor, MI) diluted 1:200 in PBS contain-
ing 1% BSA (bovine serum albumin; Fisher, Waltham,
MA). The primary antibody was omitted as a control for
non-specific antibody binding. Other primary antibodies
for immune cell markers include Bu1a (chB6; Abcam,
Cambridge, MA) and T cell antibodies (CD3, CD4, and
CD8; Southern Biotech, Birmingham, AL). As a control
for antibody specificity the anti-S1P1 was pre-absorbed
with blocking peptide (Cayman, Ann Arbor, MI) (1:1, v/
v; 45 minutes, 22°C). The absorbed, control anti-S1P1
was diluted to the same concentration as the untreated
S1P1 antibody (1:200) in normal horse serum and used
as primary antibody. Sections were washed and incu-
bated with goat anti-rabbit immunoglobulin-HRP
(Pierce/Thermo Fisher, Rockford, IL) (1:10,000 in Sigma
Blocking Buffer containing 0.05% Tween-20;1 hour; 22°
C ;S i g m a ,S t .L o u i s ,M O ) .C o l o rw a sd e v e l o p e dw i t h3 ,
3-diaminobenzidine (DAB) substrate (Vector Labs; Bur-
lingame, CA). Slides were washed in running water (15
minutes) and counterstained with hematoxylin followed
by dehydration with graded alcohol series (70 -100%)
and xylene. Sections were examined with an Olympus
light microscope (BX41, Tokyo, Japan) and an Olympus
U-CMAD3 camera with Micro Suite #5 software.
Results
S1P1 mRNA is expressed in hen tissues
The mRNA for S1P1 was detected at the predicted
amplicon size of 226 bp in hen tissue (Figure 1). Four
normal ovaries (no evidence of cancer) and four tumor
ovaries with endometrioid, serous and mucinous histol-
ogy had S1P1 mRNA (Figure 1A). Other tissues, includ-
ing muscle, oviduct, liver and kidney also contained
S1P1 mRNA (Figure 1B). The expression of S1P1
mRNA was confirmed by sequence analysis at University
of Illinois at Chicago DNA Services Facility (DNAS) and
was the positive control shown in Figure 1. The negative
control lane omitted the use of cDNA. Human tissue
was not evaluated for S1P1 mRNA expression because it
was demonstrated previously [40].
S1P1 protein is expressed in hen tissues
S1P1 protein was expressed in human and hen ovaries
and ovarian tumors with bands at 47, 72 and 108 kDa
detected by Western blot (Figure 2). There were varia-
tions in the intensity of bands at each molecular size
from different preparations in both hen and human tis-
sues. A membrane-enriched fractionation (18,000 × g)
did not result in a consistently enhanced 47 kDa band
in either the hen tissues or control rat brain. Hen brain
showed the same bands as the positive control. Spleen
was expected to express S1P1 because it is a major lym-
phocyte processing organ and the Western blot reac-
tions were the same as the rat and hen brain. The band
intensity was reduced using anti-S1P1 antibody pre-
absorbed with blocking peptide and was absent when
the primary antibody was omitted.
S1P1 localization in hen ovaries and ovarian tumors by
immunohistochemistry
S1P1 was expressed in normal hen ovaries in blood ves-
sels in the stromal (Figure 3A and 3B) and medullary
regions (Figure 3E) of the ovary. S1P1 was also found in
mature follicles, but not in early stage follicles (Figure
3A). Within mature follicles, S1P1 was expressed exclu-
sively in the theca externa (Figure 3A). Surface epithelial
cells of the ovary also showed intense S1P1 expression
(Figure 3C). Atretic follicles (Figure 3D) had S1P1+
immune cells (insert) but S1P1 staining was absent in
follicle remnants. The endothelial cells but not the
smooth muscle cells of blood vessels were S1P1+
(Figure 3E, insert).
Hen ovarian tumors had varied S1P1 staining (Figure 4).
A mucinous ovarian tumor had S1P1 staining associated
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NORMAL OVARY                         TUMOR OVARY std
E-actin
1              2     3          4 En         Sr        Mc       Mc
+   -
B
S1P1
LVR    KDNY    MSCL   OVDT                SPLEEN                      std
E-actin
1         2     3          4 
Figure 1 S1P1 mRNA expression in hen tissues.( A) S1P1 mRNA (226 bp) is expressed in both normal and tumor ovaries. Examples of mRNA
in tumors with endometrioid (En), serous (Sr), and mucinous (Mc) histology are shown. (B) Examples of other hen tissues that express S1P1
mRNA (226 bp) include liver (LVR), kidney (KDNY), skeletal muscle (MSCL), oviduct (OVDT) and spleen. Normal ovary and spleen are from the
same hens (1-4). b-actin (300 bp) was used as a loading control. Controls for S1P1 primer include the positive control (+) lane which was the
sample from an earlier experiment used to verify the RNA sequence. The negative control lane omitted the cDNA.
Figure 2 S 1 P 1p r o t e i ne x p r e s s i o ni nh e na n dh u m a nt i s s u e . S1P1 immunoreactions are similar in hen and human ovaries and ovarian
tumors. Three bands at 47, 72, 108 kDa were observed. The band at 47 kDa was faint, while bands at 72 and 108 kDa were consistently present
in all tissues but vary in intensity. The 47 kD band was not significantly enhanced using a membrane enriched (18,000 × g pellet) fraction. The
pattern of immunoreactive bands was identical in the positive control recommended by the manufacturer (rat brain) and in hen brain and
spleen. The bands were absent in control incubations in which the primary antibody was pre-adsorbed with a blocking peptide or in which the
primary antibody was omitted.
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4C). An example of a serous ovarian tumor shows light
stromal cell cytoplasmic S1P1 staining but intense stain-
ing of the surface epithelium (Figure 4E and 4F). Endo-
metrioid (Figure 4K and 4L) ovarian tumors had similar
S1P1+ staining within the tumor; the most intense stain-
ing being associated with surface epithelial cells and the
area immediately adjacent to it (Figure 4L). Most of the
S1P1+ cells associated with clear cell carcinomas were
outside the tumor (Figure 4G), while blood vessels in the
uninvolved stroma adjacent to the tumor were S1P1+
(Figure 4I).
S1P1 localization in human ovary and ovarian tumors by
immunohistochemistry
The staining patterns of S1P1 in human ovarian cancers
were heterogeneous, similar to the hen ovarian tumors.
Normal ovaries had endothelial cell S1P1 staining
around blood vessels as well as light staining of the
ovarian stroma (Figure 5A and 5C). Serous ovarian
tumors had S1P1 staining in the stroma but not the
epithelium (Figure 5B). Endometrioid tumor structures
were not stained, but surrounding stroma was S1P1
immuno-stained (Figure 5D).
S1P1 expression associated with immune cells in ovaries
of hens
Serial frozen sections of ovarian tissue were stained with
hen specific antibodies against Bu1a (antigen specific for
avian B cells) and CD3 to determine if S1P1 expression
was associated with immune cells (Figures 6 and 7). In
normal ovaries (Figure 6), S1P1 was expressed on cells
both with and without B or T cell markers in the ovar-
ian stroma and was primarily expressed on blood
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Figure 3 Localization of S1P1 receptor protein expression in normal hen ovary.( A) S1P1+ cells (black arrows) in theca of a mature follicle
(F) and within small blood vessels (BV; white arrows) in ovarian stroma (100×). Primordial follicles (f) have comparatively little S1P1+ expression.
(B) Endothelial cells of blood vessels (BV) in the theca externa (TE) of a follicle (F) and ovarian stroma are S1P1+ (200×). (C) Surface epithelial cells
(EpC) showing intense S1P1+ expression (400×). (D) An atretic follicle (af) with characteristic infiltrating S1P1+ immune cells (100×). Inset: High
magnification of (D) showing an S1P1+ immune cell (1000×). (E) Well developed blood vessels (BV) in the medullary region of the ovary also
contain S1P1+ endothelial cells (400×) but staining is lighter and more diffuse than in stromal blood vessels seen in (A) and (B). Inset: high
magnification (800×) shows detail of smooth muscle cells (SmC) and endothelial cells (EnC). (A-C) are frozen tissues; (D) and (E) are paraffin-
embedded.
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to S1P1 stained blood vessels. In tumors (Figure 7)
staining patterns were less organized. S1P1 staining
occurred in serous tumor cells. While CD4 T cells were
more often found scattered around the tumor glands,
CD8 T cells and Bu1a+ staining was localized through-
out the tissue and in tumor glands.
Discussion
This is the first study reporting the expression of S1P1
in ovarian tissues in the adult laying hen. Although
chicken specific primers were used to detect S1P1
mRNA and an anti-human S1P1 antibody was used to
detect S1P1 protein, the expression of S1P1 mRNA and
protein were correlated. Similarly, S1P1 was detected by
immunohistochemistry in tissue positive for S1P1
mRNA and protein. This is consistent with the high
degree of amino acid similarity (> 85%) between avian
[GenBank ACC#: XP_001231780.1] and human [Gen-
Bank ACC#: NP_001391.2] S1P1 protein. Furthermore
the location of S1P1 positive cells was similar in hen
and human. In normal ovaries and ovarian tumors,
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Figure 4 Localization of S1P1 receptor protein expression in hen ovarian tumors.( A) An example of a mucinous ovarian tumor with S1P1
+ staining associated with surface epithelium (black arrow) and mucin-secreting structures (black arrow) (100×). (B) H& E stained section (100×)
serial to that in (A) shows mucinous histology. (C) Higher magnification of (A) showing S1P1+ mucin-secreting glandular (MG) structures (black
arrows) (400×). (D) H&E stained section of a serous ovarian tumor (100×). (E) Serial section showing minimal stromal cell stain for S1P1+ but
intense surface epithelial cell staining (black arrow) and lighter more diffuse S1P1+ sub-epithelial cells (white arrow) (100×). (F) High
magnification (of box) showing S1P1+ surface epithelial cells (EpC) (600×). (G) Clear-cell ovarian tumor (T; left of dotted red line) with negligible
S1P1+ in tumor and S1P1+ cells in adjacent uninvolved stroma (100×). (H) H&E-stained serial section from the same tumor region in (G) shows
cellular detail of clear cell carcinoma (400×). (I) Higher magnification of box in(G) showing stromal blood vessels (BV) with S1P1+ endothelial
cells and stromal cells (S) (200×). (J) H&E stained section of late stage endometrioid tumor (100×). (K) S1P1+ is highly expressed in cells in the
tumor periphery and to a lesser extent in tumor stroma (100×). (L) High magnification of box in (K) showing cytoplasmic staining of
endometrioid tumor cells (400x). All images are from paraffin-embedded tissue, except clear cell carcinoma (G-I) which is a frozen section.
Bradaric et al. Journal of Ovarian Research 2011, 4:4
http://www.ovarianresearch.com/content/4/1/4
Page 7 of 12S1P1 was expressed in endothelial cells of blood vessels
and immune cells. In follicle cells of normal hen ovary,
theca externa cells but not ovarian stroma nor other fol-
licular structures were stained. Follicles in normal
human ovary were not observed in this study because
tissue from post-menopausal women was used and thus
it was not possible to compare them with the hen folli-
cles. Tumor cells and surface epithelium in ovaries with
tumors were variably stained. Overall the expression of
S1P1 in hen and human ovaries and in the ovarian
tumors examined was remarkably similar.
Previous reports of S1P1 detected in Western blots
indicated various molecular sizes [41], although the
expected size is 47 kDa [2]. We observed a 47 kDa spe-
cies by Western blotting in a membrane-enriched frac-
tion, although it was often faint or undetectable.
However, there were two predominant higher molecular
weight species (72 and 108 kDa); these are not usually
described although they are evident in some reports
[42]. Notably, the same molecular sizes were observed
in hen and human ovaries and ovarian tumors, hen
spleen, and hen and rat brain. Because bands react with
S1P1 antibody, the larger size bands may represent
aggregates in dimmers or trimers [43]. Alternatively,
S1P1 receptor may also be differentially glycosylated
[44]. Nonetheless, similar protein bands were detected
in the human and hen ovary, demonstrating a similar
expression pattern.
The immunohistochemical pattern of S1P1 staining
was common to both hen and human ovaries. Normal
hen ovary expressed S1P1 in surface epithelial cells,
theca cells of the follicle, endothelial cells of blood ves-
sels in the stroma and medullary region, as well as in
immune cells such as infiltrating immune cells of atretic
follicles. The expression of S1P1 was not confined to
immune cells. Because the human ovaries used in this
study were from older women, they did not have any
follicles for comparison. However, S1P1 was similarly
AB
BV
C D C D
Figure 5 S1P1 receptor expression in human ovarian carcinomas. (A) Normal ovary showing diffusely stained S1P+ stromal cells (white
arrows) and a blood vessel (BV) with intensely stained S1P1+ endothelial cells (black arrow) (200×). (B) Serous ovarian tumor with S1P1+ stroma
(white arrows) and unstained surface epithelium (200×). (C) blood vessels in normal ovary (BV, arrows) are S1P1 + (600×). (D) S1P1+
endometrioid ovarian tumor with patches of S1P1+staining within the surrounding stroma (white arrows) adjacent to unstained endometrioid
tumor (400×). (A-D) are paraffin-embedded sections.
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Page 8 of 12expressed in endothelial cells and immune cells. It is
unclear if S1P1 is expressed on the surface epithelium
of human ovarian tumors, because many of the human
ovarian tumor specimens obtained after diagnostic
pathology did not have intact surface epithelium. How-
ever, in hen and human ovarian tumors S1P1 was
expressed in endothelial cells and immune cells. In addi-
tion, tumors cells expressed S1P1 and the expression
was dispersed throughout the cytoplasm. Furthermore,
S1P1 expression varied among ovarian tumors. This
may have been due to variations in expression among
tumors or among tumor types or to sampling of indivi-
dual tumors.
Conclusion
In summary, S1P1 is expressed on immune cells in the
hen. S1P1 is also expressed in ovarian tissues of the lay-
ing hen with a distribution in the ovary that is similar to
Bu1aCD3S1P1
A
f f f
B B
C
Figure 6 In normal hen ovary S1P1 expression was observed in areas of immune cell infiltration.( Row A) Immune cells (Bu1a+ and CD3
+) are adjacent to the follicle (f) in the ovarian stroma near a transverse blood vessel (arrow in column S1P1). Cells lining the vessel near the
follicle (f) are S1P1+ (row A, S1P1) (original magnification 100×). (Row B) High magnification (see red boxes in row A) showing B and T cells
clustered within the stroma near S1P1 stained vascular endothelium (arrow). Some immune cells are also S1P1+ (open arrow) (original
magnification 400×). (Row C) Cross-section of a large blood vessel shows Bu1a and CD3 positive cells are clustered near the blood vessel. The
apical surfaces of endothelial cell express S1P1 (original magnification 100×).
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Page 9 of 12human ovaries. The chicken embryo contains both
sphingosine-1 phosphate (ligand for S1P1) and sphingo-
sine kinase; the enzyme responsible for the conversion
of sphingosine to sphingosine-phosphate which occurs
in the blood [45]. Similarly, chicken embryonic amacrine
cells were recently reported to express S1P1 [46], indi-
cating that this receptor can be found in both embryo-
nic and, as our study shows, the adult tissues of the
chicken.
We also show, for the first time, that S1P1 is
expressed in both hen and human ovarian tumors. S1P
(the ligand for S1P1) has been implicated in the traffick-
ing of immune cells [5]. Immune cells are reported to
be involved in the progression of tumors of various
organs [47]. While the role of infiltrating immune cells
in ovarian cancer progression is not clearly defined [48]
there clearly is a relationship of infiltrating T cells and
survival [48-50]. The hen provides an alternative animal
model to engineered rodent models for studies of ovar-
ian cancer. Further studies addressing immune cell infil-
tration into tumors and the role S1P1 plays in
regulating immune cell infiltration into ovarian tumors
would be facilitated by use of the hen because all stages
of spontaneous tumors in the hen can be readily
observed.
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